Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects

Part of paid clinical trials in Tucson, Arizona.

Sponsor
United Therapeutics
Study ID
NCT04084678
Phase
PHASE3
Status
Terminated

Conditions

  • Pulmonary Arterial Hypertension
  • Pulmonary Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ralinepag — DRUG
    Oral ralinepag
  • Placebo — DRUG
    Matching oral tablets

Study Details

Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment.

Key Dates

First listed
Sep 10, 2019
Start date
Jan 20, 2021
Status verified
Jun 2026
Primary completion
Apr 12, 2023
Completion
Apr 12, 2023

Study Design

Enrollment
10 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ralinepag
    Ralinepag once daily extended-release tablets (oral) 50, 250, and 400 mcg titrated to the individual maximum tolerated dose (maximum dose of 1400 mcg)
  • Placebo Comparator: Placebo
    Matching placebo tablets (oral)

Primary Outcome Measure

Change From Baseline in Peak VO2 Assessed by CPET [ Time Frame: Baseline to Week 28 ]

Locations (5)

Find similar trials in Tucson, AZ

Related Studies